Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension

Journal of Hepatology

Volumn 30, Issue 6, 1999, Pages 1105-1111

  Chu, Chi Jen ^a   Lee, Fa Yauh ^a   Wang, Sun Sang ^a   Chang, Full Young ^a   Lin, Han Chieh ^a   Lu, Rei Hwa ^a   Wu, Shwu Ling ^a   Chan, Che Chang ^a   Tai, Chun Ching ^a   Lai, I Nien ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Endotoxin; Hyperdynamic circulation; Nitric oxide; Polymyxin B; Portal hypertension; Tumor necrosis factor

Indexed keywords

CYTOKINE; DACTINOMYCIN; ENDOTOXIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYMYXIN B; TUMOR NECROSIS FACTOR ALPHA; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODYNAMICS; INTRAPERITONEAL DRUG ADMINISTRATION; LIMULUS LYSATE TEST; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RAT; THERMODILUTION; VASODILATATION; VEIN LIGATION;

EID: 0033064364     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80266-9     Document Type: Article

References (52)

1. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 244:1983;G52-G57.
2. Schrier RW, Caramelo C. Hemodynamic and hormonal alterations in hepatic cirrhosis. Epstein M., The Kidney in Liver Disease. 1988;265-285 Williams and Wilkins, Baltimore.
3. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 43:1991;109-142.
4. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology. 103:1992;235-239.
5. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology. 16:1992;1043-1048.
6. Pizcueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide synthase on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol. 105:1992;184-190.
7. ω-nitro-L-argninine administration corrects peripheral vasodilatation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology. 17:1993;84-90.
8. Xie QW, Whisnant R, Nathan C. Promotor of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon-γ and bacterial lipopolysaccharide. J Exp Med. 177:1993;1779-1784.
9. Laskin DL, Heck DE, Gardner CR, Feder LS, Laskin JD. Distinct patterns of nitric oxide production in hepatic macrophages and endothelial cells following acute exposure of rats to endotoxin. J Leukoc Biol. 56:1994;751-758.
10. So S, Hattori Y, Kasai K, Shimoda SI, Gross SS. Up-regulation of rat adrenomodullin gene expression by endotoxin: relation to nitric oxide synthesis. Life Sci. 58:1996;PL309-PL315.
11. Gross SS, Jaffe EA, Levi R, Kilbourn RG. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun. 178:1991;823-829.
12. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin 1, or endotoxin. J Natl Cancer Inst. 82:1990;772-776.
13. Old LI. Tumor necrosis factor (TNF). Science. 230:1985;630-632.
14. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 337:1991;776-778.
15. Lee FY, Wang SS, Yang MCM, Tsai YT, Wu SL, Lu RH, et al. Role of endotoxemia in hyperdynamic circulation in rats with extrahepatic or intrahepatic portal hypertension. J Gastroenterol Hepatol. 11:1996;152-158.
16. Metha R, Gottstein J, Zeller WP, Lichtenberg R, Blei AT. Endotoxin and hyperdynamic circulation of portal vein-ligated rats. Hepatology. 12:1990;1152-1156.
17. Le Moine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al. Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. J Hepatol. 23:1995;391-395.
18. Garcia-Tsao G, Albillos A, Barden GE, Weat AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 17:1993;1081-1085.
19. Sorell TW, Quigley EMM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal-hypertensive rats: studies in basal condition and on exposure to hemorrhagic shock. Gastroenterology. 104:1993;1722-1726.
20. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, Weat AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology. 108:1995;1835-1841.
21. Genecin P, Colombato LA, Ferraioli G, Groszmann RJ. Neomycin reduces ammonia levels without ameliorating the hyperdynamic circulation in two portal hypertensive rat models. [abstract] Hepatology. 10:1989;586A.
22. Lynn WA, Golenbock DT. Lipopolysaccharide antagonists. Immunology Today. 13:1992;271-276.
23. Galanos C, Luderitz O, Rietschel ET, Westphal O, Brade H, Brake L, et al. Synthetic and Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem. 148:1985;1-5.
24. Form AH, Fong JS, Good RA. Polymyxin B sulphate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun. 23:1979;660-664.
25. Hughes B, Madan BR, Parratt JR. Polymyxin B sulphate protects cats against the hemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol. 74:1981;701-707.
26. Flynn PM, Shenep JL, Stokes DC, Fairclough D, Hildner WK. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis. 156:1987;706-712.
27. Pieroni RE, Broderick EJ, Bundereally A, Levine L. A simple method for the quantitation of submicrogram amounts of bacterial endotoxin. Proc Soc Exp Biol Med. 133:1970;790-794.
28. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol. 240:1981;G371-G375.
29. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology. 102:1992;931-935.
30. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver disease: relationship to the severity of liver disease, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 22:1995;165-172.
31. Fukui H, Brauner B, Bode JC, Bode C. Chromogenic endotoxin assay in plasma selection of plasma pretreatment and production of standard curves. J Clin Chem Clin Biochem. 27:1989;941-946.
32. Fernández M, Garcia-Pagán JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology. 108:1995;1487-1495.
33. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumor necrosis factor-α and nitric oxide. Clin Sci. 93:1997;219-225.
34. Ruiter DJ, Van der Meulen J, Brouwer A, Hummel MJ, Mauw BJ, Van der Ploeg JC, et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest. 45:1981;38-45.
35. Munford RS, Hall CL. Uptake and deacylation of bacterial lipopolysaccharide by macrophages from normal and endotoxin-hyporesponsive mice. Infect Immun. 48:1985;464-473.
36. Fukuda I, Tanamoto K, Kanegasaki S, Yajima Y, Goto Y. Deacylation of bacterial lipopolysaccharide in rat hepatocytes in vitro. Br J Exp Pathol. 70:1989;267-274.
37. ω-nitro-L-arginine ameliorates portal-systemic shunting in portal hypertensive rats. Gastroenterology. 105:1993;1464-1470.
38. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol. 248:1985;G618-G625.
39. Almdahl SM, Østerud B, Melby K, Giercksky KE. Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis. Acta Chir Scand. 152:1986;351-355.
40. Lundblad R, Nesland JM, Giercksky KE. Granulocyte colonystimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med. 24:1996;820-826.
41. Baldwin G, Alpert G, Caputo GL, Baskin M, Parsonnet J, Gillis ZA, et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis. 164:1991;542-549.
42. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 8:1988;232-236.
43. Dijkstra HM, Manson WL, Klasen HJ, Van der Waaij D. Effect of polymyxin B on intestinal bacterial translocation in Pseudomonas aeruginosa wound-colonized burned mice. Eur Surg Res. 24:1992;69-76.
44. Yao YM, Tian HM, Sheng ZY, Wang YP, Yu Y, Sun SR, et al. Inhibitory effect of low-dose polymyxin B on hemorrhage-induced endotoxin/bacterial translocation and cytokine formation in rats. J Trauma. 38:1995;924-930.
45. Endo S, Inada K, Kikuchi M, Yamada Y, Takakuwa T, Nakae H, et al. Clinical effects of intramuscular administration of a small dose of polymyxin B to patients with endotoxemia. Res Commun Chem Path. 83:1994;223-235.
46. Endo S, Inada K, Inoue Y, Fujii N, Yamada Y, Takakuwa T, et al. Treatment of endotoxemia with low-dose intramuscular injection or oral administration of polymyxin B. Clin Ther. 14:1992;64-67.
47. Garcia-Pagán JC, Fernández M, Bernadich C, Pizcueta P, Pique JM, Bosch J, et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol. 267:1994;G984-G990.
48. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 108:1995;761-767.
49. Lopez-Talavera JC, Cadelina G, Merrill WW, Groszmann RJ. Role of tumor necrosis factor-alpha in the circulatory abnormalities of cirrhotic rats. [abstract] Hepatology. 22:(suppl):1995;256A.
50. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal hypertensive rats. Hepatology. 23:1996;1616-1621.
51. Chu CJ, Lee FY, Chang FY, Wang SS, Lin HC, Wu SL, et al. Hyperdynamic circulation in prehepatic portal hypertension: role of tumor necrosis factor-α Chin Med J (Taipei). 59:1997;145-150.
52. Ohta M, Tarnawski AS, Itani R, Pai R, Tomikawa M, Sugimachi K, et al. Tumor necrosis factor α regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology. 27:1998;906-913.